Drug
Mezigdomide clinical trials
Also written CC-92480 and BMS-986348.
- studies test it
- 22
- open now
- 11
- in phase 3
- 2
- first study started
- 2018
Keep track of what changes. Save the mezigdomide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2023 (5)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 19
- Phase 2
- 6
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 9
Celgene (8) · Bristol-Myers Squibb (3) · Memorial Sloan Kettering Cancer Center (2) · Massachusetts General Hospital (2) · Abdullah Khan (1) · K36 Therapeutics, Inc. (1) · AbbVie (1) · Roswell Park Cancer Institute (1)
Often tested with
Tested in the same studies.
Dexamethasone (5) · Carfilzomib (3) · Pomalidomide (3) · Elranatamab (2) · Elotuzumab (1) · Rifampin (1) · Itraconazole (1) · Digoxin (1)
Studies
Open first, then newest update. How each study uses mezigdomide is read from its arms, and is right about nine times in ten.
Testing it · 22
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingPhase 1K36 Therapeutics, Inc.NCT05651932Written as Cohort B1 & B2: KTX-1001+Mezigdomide
- A Study of Revumenib and Mezigdomide in People With LeukemiaRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT07356154Written as Mezigdomide
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingPhase 1/2AbbVieNCT06892522Written as Mezigdomide
- A Study of Teclistamab and Mezigdomide in People With Multiple MyelomaRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07105059Written as Mezigdomide
- Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AMLRecruitingPhase 1Massachusetts General HospitalNCT07355335Written as Mezigdomide
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingPhase 3CelgeneNCT05519085Written as mezigdomide
- A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingPhase 1/2CelgeneNCT06988488Written as Mezigdomide
- Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary DiseaseRecruitingPhase 2Roswell Park Cancer InstituteNCT06627751Written as Mezigdomide
- Mezigdomide and Talquetamab in Relapsed and Refractory Multiple MyelomaRecruitingPhase 1Massachusetts General HospitalNCT07032714Written as Mezigdomide
- Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple MyelomaRecruitingPhase 1City of Hope Medical CenterNCT06048250Written as Mezigdomide
- Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple MyelomaRecruitingPhase 1/2YOUNGIL KOHNCT06645678Written as Mezigdomide
- A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)Active, not recruitingPhase 3Bristol-Myers SquibbNCT05552976Written as Mezigdomide
- Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted TherapiesActive, not recruitingPhase 1Abdullah KhanNCT05981209Written as Mezigdomide
- A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple MyelomaTerminatedPhase 1CelgeneNCT06163898Written as Mezigdomide
- A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal ImpairmentCompletedPhase 1CelgeneNCT06318676Written as Mezigdomide
- Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple MyelomaWithdrawnPhase 1/2Kathleen DorritieNCT06050512Written as Mezigdomide
- A Study of Mezigdomide in Healthy Participants and Participants With Hepatic ImpairmentCompletedPhase 1Bristol-Myers SquibbNCT05707390Written as Mezigdomide
- A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05389722Written as CC-92480
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult ParticipantsCompletedPhase 1CelgeneNCT04839809Written as CC-92480
- A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male ParticipantsCompletedPhase 1CelgeneNCT04560738Written as [14C]-CC-92480
See all 22 studies that test mezigdomide →
Given in every arm · 5 — mezigdomide is usual care beside what is tested
- A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingPhase 1Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06121843Written as Mezigdomide
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingPhase 1/2Karyopharm Therapeutics IncNCT02343042Written as Mezigdomide
- A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1/2Bristol-Myers SquibbNCT05372354Written as CC-92480
- A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)TerminatedPhase 1/2CelgeneNCT03374085Written as CC-92480
- A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)Active, not recruitingPhase 1/2CelgeneNCT03989414Written as CC-92480
Codes
What other systems call mezigdomide · ClinicalTrials.gg INT017163
- UNII (FDA) LA88IH4O02MEZIGDOMIDEConfirmed FDA, Wikidata
- Wikidata Q123914054mezigdomideConfirmed FDA, Wikidata
- NCI Thesaurus C146660MezigdomideOne source FDA
- DrugBank DB17584One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LA88IH4O02 | MEZIGDOMIDE | Confirmed FDA, Wikidata |
| Wikidata | Q123914054 | mezigdomide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C146660 | Mezigdomide | One source FDA |
| DrugBank | DB17584 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.